Insider Transactions in Q3 2023 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2023
|
Albert Cha Director |
SELL
Open market or private sale
|
Direct |
18,000
-100.0%
|
$180,000
$10.5 P/Share
|
|
Sep 11
2023
|
Albert Cha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+45.0%
|
$126,000
$7.3 P/Share
|
|
Aug 18
2023
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
14,876
-9.2%
|
$148,760
$10.73 P/Share
|
|
Aug 18
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
13,067
-12.06%
|
$130,670
$10.73 P/Share
|
|
Aug 18
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,142
-14.63%
|
$71,420
$10.73 P/Share
|
|
Aug 18
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,976
-6.36%
|
$49,760
$10.73 P/Share
|
|
Aug 18
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,020
-23.56%
|
$80,200
$10.73 P/Share
|
|
Aug 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,582
+17.2%
|
-
|
|
Aug 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,195
+21.8%
|
-
|
|
Aug 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+19.06%
|
-
|
|
Aug 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+12.81%
|
-
|
|
Aug 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,529
+35.25%
|
-
|